• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    MannKind Corporation - Common Stock (NQ:MNKD)

    5.600 -0.070 (-1.23%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,733,096
    Open 5.730
    Bid (Size) 5.580 (10,300)
    Ask (Size) 5.730 (5,000)
    Prev. Close 5.670
    Today's Range 5.575 - 5.730
    52wk Range 3.381 - 6.680
    Shares Outstanding 264,305,532
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares? ↗
    This biotech innovator in inhaled therapeutics reported a notable insider sale amid ongoing product development and licensing activity. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why a Fund Trimmed an $18 Million Stake in Primo Brands Amid a 47% Stock Drop ↗
    With shares battered and leverage rising, this quiet trim raises a sharper question about how much patience investors should have left. 
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    N/A
    N/A
    1 Month
    +0.2%
    +0.2%
    3 Month
    -2.8%
    -2.8%
    6 Month
    +58.2%
    +58.2%
    1 Year
    -15.2%
    -15.2%

    More News

    Read More
    News headline image
    Lantheus Exit: $28 Million Sale Comes as Earnings Fall 77% Year Over Year ↗
    Via The Motley Fool
    Topics Regulatory Compliance Supply Chain
    MannKind Stock Slips Despite FDA Clearing Pediatric Use Of Heart Failure Drug — What’s Spooking Investors? ↗
    Via Stocktwits
    MannKind Stock Nears Breakout As FDA Reviews First New Insulin For Kids In A Century ↗
    Via Stocktwits
    MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters ↗
    Via Stocktwits
    News headline image
    Earnings Scheduled For November 5, 2025 ↗
    Via Benzinga
    News headline image
    MannKind Shares FUROSCIX® Business Updates
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind to Present at the Jefferies Global Healthcare Conference
    From MannKind
    Via GlobeNewswire
    MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results ↗
    Via Stocktwits
    News headline image
    MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind Corp (NASDAQ:MNKD) Reports Q3 2025 Earnings Beat, Shares Rise ↗
    Via Chartmill
    Topics Earnings
    News headline image
    MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer
    From MannKind
    Via GlobeNewswire
    News headline image
    10 Health Care Stocks Whale Activity In Today's Session ↗
    Via Benzinga
    News headline image
    Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
    Via Benzinga
    News headline image
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill
    News headline image
    Tuesday's pre-market session: top gainers and losers ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: scPharmaceuticals Inc. (Nasdaq – SCPH), Vital Energy, Inc. (NYSE – VTLE), International Money Express, Inc. (Nasdaq - IMXI), HanesBrands Financial Corp. (NYSE - HBI)
    From Brodsky & Smith LLC
    Via GlobeNewswire

    Frequently Asked Questions

    Is MannKind Corporation - Common Stock publicly traded?
    Yes, MannKind Corporation - Common Stock is publicly traded.
    What exchange does MannKind Corporation - Common Stock trade on?
    MannKind Corporation - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for MannKind Corporation - Common Stock?
    The ticker symbol for MannKind Corporation - Common Stock is MNKD on the Nasdaq Stock Market
    What is the current price of MannKind Corporation - Common Stock?
    The current price of MannKind Corporation - Common Stock is 5.600
    When was MannKind Corporation - Common Stock last traded?
    The last trade of MannKind Corporation - Common Stock was at 01/02/26 04:00 PM ET
    What is the market capitalization of MannKind Corporation - Common Stock?
    The market capitalization of MannKind Corporation - Common Stock is 1.48B
    How many shares of MannKind Corporation - Common Stock are outstanding?
    MannKind Corporation - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.